A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria:

   - Participants who are 16 to 17 years old would be enrolled after consultation with the
   Medical Monitor

   - Histologically or cytologically documented, incurable or metastatic solid tumor or
   hematologic malignancy that is advanced (non-resectable) or recurrent and progressing
   since the last anti-tumor therapy and for which no recognized standard curative
   therapy exists

   - Representative tumor specimens in paraffin blocks (preferred) or at least 15 unstained
   slides, with an associated pathology report

   - Adequate hematologic and end organ function

   - Measurable disease per RECIST v1.1 for participants with solid malignancies.
   Disease-specific criteria for participants with prostate cancer, glioblastoma
   multiforme (GBM), malignant lymphoma, or multiple myeloma

   - For women of childbearing potential: agreement to remain abstinent or use
   contraceptive methods

   - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

   - For participants who will undergo serial biopsy in dose-escalation cohort, baseline
   tumor tissue samples should be of core needle biopsies for deep tumor tissue or organs
   or excisional or punch biopsies for cutaneous or subcutaneous lesions (>/=5 millimeter
   [mm] in diameter amenable to serial biopsy)

Exclusion Criteria:

   - Known primary central nervous system (CNS) malignancy or symptomatic CNS metastases

   - Known hypersensitivity to pharmaceuticals produced in Chinese hamster ovary cells or
   any component of the atezolizumab formulation

   - History or risk of autoimmune disease (for example, systemic lupus erythematosus,
   rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with
   antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Bell's palsy,
   Guillain-Barré syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis,
   or glomerulonephritis)

   - History of human immunodeficiency virus (HIV) infection, active hepatitis B (chronic
   or acute), or hepatitis C infection

   - Signs or symptoms of infection within 2 weeks prior to Cycle 1, Day 1

   - Malignancies other than disease under study within 5 years prior to Cycle 1, Day 1

   - Participants with prior allogeneic bone marrow transplantation or prior solid organ
   transplantation